A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19

• Main Authors: Junsaku Kitagawa (Author), Hayato Arai (Author), Hiroyuki Iida (Author), Jiro Mukai (Author), Kenji Furukawa (Author), Seitaro Ohtsu (Author), Susumu Nakade (Author), Tomohiro Hikima (Author), Miwa Haranaka (Author), Naoto Uemura (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis. Recently, camostat mesylate and its active metabolite 4‐(4‐guanidinobenzoyloxy)phenylacetic acid (GBPA) were reported to inhibit the infection of cells by severe acute respira...